Finanzas de Entera Bio Ltd (ENTX)ENTXEntera Bio Ltd

Evaluating the bottom line, Entera Bio Ltd maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -138.92%, provide a clear picture of how effectively ENTX converts its operational activities into shareholder value.

In the context of the broader market, ENTX competes directly with industry leaders such as EOLS and AQST. With a market capitalization of $511.33M, it holds a leading position in the sector. When comparing efficiency, ENTX's gross margin of N/A stands against EOLS's 66.19% and AQST's 70.93%. Such benchmarking helps identify whether Entera Bio Ltd is trading at a premium or discount relative to its financial performance.

Entera Bio reported a net loss of $7.31 million for Q2 2026, with a projected EPS of -0.14, indicating financial challenges. However, the company has a strong current ratio of 8.98, suggesting good short-term financial health.